Xenogeneic cell (fragment) transplantation may be used as an interim therapy until the organ allotransplanation. Immunologic rejection, however, constitutes the major hurdle. To overcome this problem, "xeno" fetal and neonatal liver fragments (FLF, NLF) were encapsulated into separate micropore devices that protect them from immunological attack by the recipient. The FLF or NLF were then transplanted into beagles with hepatic failure to observe their biological effects. In Experiment 1 (n = 5) beagles were injected IV with Dgalactosamine (D-gal, 1.0 g/kg) on day 0 and then received FLF grafts (0, 0.3, 0.8, 1.0, 2.0 g/kg). In Experi ment 2 (n = 6) beagles received NLF grafts (1.8 g/kg) and on the following day were injected with D-gal (1.0 g/kg). In Experiment 1 only the high dose of xeno-FLF (2.0 g/kg) decreased the elevated ALT (GPT) and T. Bil. levels. Histologic examination showed that some of the hepatocytes of the host liver survived only in the high-dose graft. In Experiment 2, at 36 and 48 h after D-gal injection, the transplanted group had a significantly lower AST (GOT) level than the control. The grafted NLF survived for 14 days, according to histologic examinations. Thus, encapsulated FLF and NLF xenotransplantation can prevent liver dysfunc tion in a large animal hepatic failure model.
INTRODUCTION
Until organ allotransplantation comes into general use, xenogeneic cell (fragment) transplantation can be used as an interim therapy. However, immunologic re jection can occur, and constitutes a major handicap (4) .
To overcome this problem, we xenografted organs im munologically protected by a micropore-sized capsule.
We have already observed the positive effect of a pro tected xenografted organ in small animal models (8, 9) .
As an interim therapy, if these methods are used for liver allotransplantation in the case of hepatic failure, the protection offered by the immunocapsules against host immunological attack must be tested in a large ani mal model. Canines have been used as large animals for hepatic failure models by several researchers (2, (5) (6) (7) , and D-galactosamine (D-gal) has been used to induce he patic failure in large and small animal models (1, 2, 5, 8) .
In the present study, we investigated the effects of encapsulated pig fetal liver fragments (FLF) and neona tal liver fragments (NLF) grafted into the greater omen tum in a large animal model of chemically (D-gal) in duced hepatic failure.
MATERIALS AND METHODS

Animals
Miniature swine fetuses between 100 and 110 days of gestational age and Landrace-Duroc-Yorkshire swine neonates were obtained on day 0 or 1 of birth from Nip pon Institute for Biological Science (Tokyo, Japan) and
Cimco Corporation (Chiba, Japan), respectively. The fe tuses, weighing 300-500 g, were taken from the preg nant dams by cesarean section under sterile conditions, and full-term pigs, weighing 1000-1500 g, were taken from their dams as neonates under sterile conditions. The fetal and neonatal livers were resected under sterile conditions and cut into pieces of approximately 1-3 mm 3 in size in a cold RPMI-1640 medium. Those frag ments were immersed in 10% DMSO, 40% FBS, and 50% RPMI medium and cryopreserved in liquid nitro gen at -196°C. The cryopreserved liver fragments were thawed in a 37°C water bath and washed with RPMI-1640 three times. Thawed liver fragments (altogether 1.0 g) were placed in an immunocapsule with a small pipette and used as the graft for one recipient beagle. Japan, Ltd. (Tokyo, Japan) were used as recipients. All animals were kept in specific pathogen-free (SPF) con dition.
Macrocapsule
The immunocapsule (Celgard 2500 celanese; Hoechst) consists of a microporous polypropylene mem brane, 25 \i thick with 0.075 x 0.25 a pores. This mem brane allows molecules of molecular weights (MW) less than 80,000 to penetrate it. The macrocapsules were 20 x 40 mm in size, sterilized by gas sterilization, and kept in sterilized RPMI medium before use.
Procedure
Beagles were premedicated with atropine sulfate 0.1 mg/kg and Selakutar 0.1 mg/kg intramuscular (IM) in jection. Ketamine hydrochloride (0.1 or 0.24 mg/kg IM, or 0.24 mg/kg/h IV infusion) was used for induction of anesthesia. After endotracheal intubation, anesthesia consisting of 20% 0 2 and continuous IV administration of ketamine was performed. All animals underwent uni lateral external jugular cannulation with a subcutaneous tunnel using polyurethane single lumen catheters.
The immunocapsules, each containing 300-400 pieces of pig fetal or neonatal liver fragments, were transplanted into the greater omentum of the recipient large animals. D-Galactosamine (Sigma Chemicals, St. Louis, MO) was dissolved in 0.9% NaCl to a concentration of 0.1 g/ ml, and the pH was adjusted to 6.8 with 1 mol/1 NaOH. The solution was filter sterilized and injected via the jugular catheter within 2 h of preparation.
Experimental Design Experiment 1. On day 0, five beagles were injected IV with D-gal (1.0 g/kg) and immediately after injection received intraomental transplants of different doses of encapsulated FLF (0, 0.3, 0.8, 1.0, 2.0 g/kg) ( Fig. la) . 
RESULTS
Experiment 1
The low doses of xeno-FLF (0.3-1.0 g/kg) could not prevent the elevation of transaminase, whereas the high dose of FLF (2.0 g/kg) decreased it. The levels of T. Bil. in the xenografted animals examined at various different times (24 and 36 h) after the induction of hepatic failure were relatively low compared to the control ( Table 1 ). The levels of GOT (AST) and GPT (ALT) in the control animals examined at various different times after the in duction of hepatic failure were relatively low compared to the xenografted animals ( Table 1 ). There were no sta tistically significant differences of all biochemical labo ratory data and coagulation profile between the grafted group and the control group (data not shown). The sur vival rate of the hosts was not increased, and they were dead within 72 h after D-gal injection.
Histopathologic examination (using H&E-stained sections) of the host livers showed severe necrosis when the low doses of FLF were transplanted into the recipi ents, whereas the destruction of the host liver structure and the damage to hepatocytes in the high-dose group was significantly less than that in the low-dose and con trol groups (Fig. 2) .
Experiment 2
The NLF xenografts (1.8 g/kg) protected the host after the induction of hepatic failure. The levels of GOT (AST) and GPT (ALT) in the xenografted animals ex amined at various times after the induction of hepatic failure were still much lower than those in nongrafted animals ( Table 2) ; the level of GOT (AST) was signifi cantly lower in xenografted animals than in control (p < 0.05). However, there were no statistically significant differences in the other biochemical laboratory data and coagulation profile between the grafted group and the control group (data not shown).
Histopathologic examination showed that the damage in the host liver was different between the groups. The major damage was observed in nontransplanted animals. In animals that received NLF grafts, damage was minor and slight congestion was observed. In their livers, al most normal morphology was maintained (Fig. 3) . The hepatocytes of grafted NLF also showed a normal he patic structure (Fig. 3) . in acute hepatic failure is also effective therapy, as some investigators have reported (1, 8, 10) . We have already observed the beneficial effects of porcine fetal liver fragment xenotransplantation in a rat model (3, 8, 9) . The reasons why we used the fetal liver fragments are two fold: 1) fetal liver has the capacity to proliferate; 2) fetal liver has a low immunogenicity (9) .
DISCUSSION
Recently we have used the immunocapsule for xeno transplantation, and have observed that it protects the grafts from host immunologic attack and prolongs the survival time of those grafts (3, 8, 9) . In the present study, Our previous experiment in a rat model was also performed using this timing (8) . In this study, the protocol of Experiment 1 was to perform transplantation immediately after D-gal was injected. For Experiment 2, we modified the protocol and NLF transplantation was performed 1 day earlier (day -1) and D-gal was injected on day 0 (as described in Materials and Methods). In Experiment 1 the effect was not significantly different from that shown in Experiment 2, which indicates that NLF (FLF) grafts are beneficial in a large animal model.
These data indicate that FLF/NLF in an immunocap sule can effectively protect hepatic cells from host im munologic attack and can prevent increases in hepatic These data (the results of Experiment 2) also suggest that some factor from FLF/NLF has a good effect on the normal liver. This factor is considered to be a kind of hepatogrowth factor.
In conclusion, xenotransplantation of encapsulated fetal and neonatal porcine liver fragments (FLF, NLF)
can prevent liver dysfunction in a large animal hepatic failure model. This therapy is intended for use in the treatment of fulminant hepatic failure patients.
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